What can you try if Keytruda (pembrolizumab) isn’t working?
If Keytruda stops working or your disease progresses while on it, the next step depends mainly on the cancer type, how the tumor responded previously, and whether there are specific biomarkers (like PD‑L1 or MSI‑H status). Common real-world alternatives fall into a few buckets: switching to a different immunotherapy, moving to chemotherapy, targeting a mutation if one is present, or using a different combination of drugs.
Because “Keytruda not working” can mean different situations (progression during treatment vs. relapse after stopping), clinicians typically reassess:
- The exact cancer type and stage
- Prior lines of therapy already used
- Current performance status and treatment goals
- Biomarkers (tumor genetics and immunotherapy markers)
- Whether the cancer is growing “slowly” (sometimes prompting a regimen change vs. immediate escalation)
Switching to another immunotherapy: what’s usually considered?
For many cancers, options after Keytruda may include a different immune checkpoint approach or an immunotherapy combination that changes the mechanism.
Examples of strategies clinicians consider include:
- Trying another checkpoint inhibitor (same “immunotherapy class,” different drug)
- Using checkpoint inhibitors in combination with chemotherapy or other targeted drugs to improve response chances
- Considering treatment only if the tumor’s biomarkers suggest higher likelihood of benefit
The exact drug choice varies widely by tumor type (for example, lung cancer vs. melanoma vs. kidney cancer), so the best-fit alternative is different for each indication.
If immunotherapy isn’t working: do chemotherapy options still make sense?
Yes. When checkpoint inhibitors aren’t controlling disease, chemotherapy remains a common alternative. It can work even when immunotherapy doesn’t, especially if:
- The cancer biology doesn’t respond to checkpoint blockade
- There’s rapid progression and the need for disease control
- Options for targeted therapy or clinical trials aren’t available
Chemotherapy regimens are also tailored to the cancer type, prior treatments, and patient tolerance.
Targeted therapy: what if there’s a mutation Keytruda doesn’t address?
Some tumors have actionable genetic changes where targeted therapy can be more effective than immunotherapy alone. Clinicians often order or review molecular testing when Keytruda fails to see whether any of the following are present (examples vary by cancer type):
- Driver mutations that have approved targeted drugs
- Biomarkers that predict benefit from specific targeted regimens
If actionable mutations are found, switching to a targeted therapy (or a targeted + immunotherapy combination) can be a major next step.
Clinical trials: a frequent next option after Keytruda failure
When standard options are limited, clinical trials often become one of the most important alternatives. Trials may test:
- New checkpoint agents or novel combinations
- Treatments designed for resistance after prior PD‑1 therapy
- Targeted therapies for less common mutations
If you tell me the cancer type and what lines of therapy you’ve already had, I can help you think through the kinds of trial strategies that are commonly offered.
Key practical question: was Keytruda stopped for side effects or because it didn’t work?
This matters because “alternative” options differ when Keytruda is discontinued due to:
- Immune-related side effects (dose hold, switch of regimen, or sometimes restarting immunotherapy depending on severity and recovery)
- True progression (new regimen, often with a different mechanism)
Also, if you developed immune side effects, the oncology team will consider whether any future immunotherapy is safe based on how severe the reaction was.
What to ask your oncologist next (so you get a real plan)
If you’re trying to decide the next treatment option after Keytruda, these questions usually guide the decision quickly:
- What exactly does “not working” mean here (progression on-treatment vs. relapse after stopping)?
- What biomarkers were tested (PD‑L1, MSI-H/dMMR, tumor genetics)?
- What prior treatments have you already received, and what options remain?
- Are there approved alternatives for your specific cancer type?
- Is a clinical trial available that targets resistance to prior PD‑1 therapy?
- What side-effect risks are most likely with the next regimen?
If you share 3 details, I can narrow alternatives
1) Cancer type (and where it is: metastatic or local)
2) Whether it failed during Keytruda or after finishing it (and roughly when)
3) Any biomarker or mutation results you have (PD‑L1, MSI/dMMR, EGFR/ALK/BRAF, etc.)
With that, I can list the most relevant categories of alternatives and how doctors typically sequence them.